EPO Biomarkers Market Trends, Size, Share, Industry Analysis and Forecast - 2025


Posted July 14, 2020 by farazp70

Some of the EPO biomarkers available in the market are epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, recombinant human erythropoietin, and darbepoetin alfa.

 
Erythropoietin (EPO) is a hormone that is produced from the kidney inside the human body. EPO biomarkers Market are used to increase the growth of red blood cells in the body by stimulating the bone marrow. Some of the EPO biomarkers available in the market are epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, recombinant human erythropoietin, and darbepoetin alfa. Erythropoietin alfa is used to treat anemia and cancer cells and it increases the count of red blood cells in the body. Erythropoietin is mostly administered as an alternative to iron supplements. Moreover, the erythropoietin biomarkers are used to treat end-stage renal diseases (ESRD), and anemia induced from multiple myeloma, cancer, and AIDS associated anemia.

Get Sample Copy of EPO Biomarkers Market at: https://www.omrglobal.com/request-sample/epo-biomarkers-market

Some of the key players operating in the global EPO biomarkers market are Siemens AG, Thermo Fisher Scientific, Pfizer Inc., Novartis AG, Johnson & Johnson Services, Inc., Merck KGaA, LG Lifesciences Pvt Ltd, Amgen Inc., F. Hoffmann-LA Roche Ltd, and Agilent Technologies, Inc., among others.

Major factors contributing to the growth of the global EPO biomarkers market include increasing sedentary lifestyle and faulty dietary habits has increased the prevalence of cancers and chronic kidney diseases in the emerged economies. Moreover, the increasing incidence of end-stage renal disorders and hematological diseases is further increasing the demand for EPO biomarkers. The patent expiration of EPO biomarkers is significantly increasing the introduction of novel EPO biomarkers in the market. However, the lack of quality control testing laboratories in emerging economies such as India and China is a major factor hindering the growth of the market. Improper price capping regulations across the globe is another factor that is significantly responsible in hampering the growth of the global EPO biomarkers market. However, the favorable healthcare regulations in emerged economies such as the U.S. and rising prevalence of chronic diseases such as cancer is expected to fuel the market growth in the near future.

For More Information, get A full report of EPO Biomarkers Market is available at: https://www.omrglobal.com/industry-reports/epo-biomarkers-market

The EPO Biomarkers Market can be segmented on the basis of biomarker type, applications, and end users. Based on biomarker type, the market is segmented into erythropoietin alfa, erythropoietin beta, erythropoietin zeta, erythropoietin theta, recombinant human erythropoietin, and darbepoietin alfa. Based on application, the market is bifurcated into end-stage renal disorder, cancers, rheumatoid arthritis, AIDS, myelodysplastic syndrome, neurology, hematology, and others (anaemia of chronic inflammatory syndromes). Based on end users, the market is segmented into diagnostic centers, ambulatory care and surgical centres, and hospitals. Among biomarker type, the erythropoietin alfa segment holds a major share in the global EPO biomarkers market. This is owing to increasing adoption in the treatment of chronic renal disorders and cancer.

The global EPO biomarkers market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America holds a dominant position in the global EPO biomarkers market, followed by Europe. This is mainly owing to the developed healthcare infrastructure in the region. Moreover, the systematic initiatives taken by the government in the research and development activities is one of the major factors contributing in the growth of the EPO biomarkers market in the region. Asia Pacific is projected to exhibit the fastest growth in the global market over the forecast period. Some of the major factors that are significantly contributing in the growth of the market in Asia Pacific are low cost of treatment therapy and increasing incidence rate of hematological diseases in the region, especially in India, China, Pakistan, and Bangladesh.

Market segmentation

By Biomarker Type

Erythropoietin alfa
erythropoietin beta
Erythropoietin zeta
erythropoietin theta
recombinant human erythropoietin
darbepoietin alfa

By Applications

End-Stage Renal Disorder
Cancers
Rheumatoid Arthritis
Aids
Myelodysplastic Syndrome
Neurology
Hematology
Others (Anaemia of Chronic Inflammatory Syndromes)

By End Users

Diagnostic Centres
Ambulatory Care and Surgical Centres
Hospitals

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/epo-biomarkers-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Mr. Anurag Tiwari
Country India
Categories Business , Services , Technology
Last Updated July 14, 2020